Preliminary clinical investigation of 18F-(2S,4R)-4-fluoroglutamine PET/CT in the evaluation of lung cancer
European Journal of Nuclear Medicine and Molecular Imaging · 2026-11 · 53 (13) · 8166-8176
DOI: 10.1007/s00259-026-08107-7 ↗Kurz gefasst
Beobachtungsstudie in der Zeitschrift European Journal of Nuclear Medicine and Molecular Imaging, online erschienen am 06.08.2026. Verfasst von Xiaoxia Xu und 5 weiteren Autor:innen. Beteiligte Einrichtung: Key laboratory of Carcinogenesis and Translational Research (Ministry of Education), Beijing Key Laboratory of Research, Investigation and Evaluation…. Hauptthemen laut MEDLINE: Glutamine, Lung Neoplasms, Positron Emission Tomography Computed Tomography. Die Arbeit nennt 34 Literaturangaben. Gefördert von: National Natural Science Foundation of China, Beijing Hospitals Authority's Ascent Plan, Beijing Hospitals Authority’s Ascent Plan.
Abstract (Originalsprache)
BACKGROUND: The clinical utility of 18F-fluoroglutamine (18F-FGln) PET/CT for characterizing metabolic heterogeneity and improving lung cancer staging remains underexplored. METHODS: In this prospective study, 31 patients with 36 primary lung lesions underwent dual-tracer (18F-FDG/18F-FGln) PET/CT. A metastatic cohort (n = 28) was analyzed for distant staging. Diagnostic performance was assessed using ROC analysis, logistic regression, and radiomic texture parameters (volume, mass, CT histogram features). RESULTS: For primary lesions, 18F-FDG showed marginally higher detection rates (86.1% vs. 80.6%) and significantly greater avidity (SUVmax: 9.15 ± 0.16 (FDG) vs. 3.94 ± 1.57 (FGln), P < 0.001). CT texture analysis revealed kurtosis as an independent predictor of 18F-FGln uptake (OR = 1.16, P = 0.025), correlating with metabolic-structural coupling (r = 0.445, P = 0.009). In nodal staging, 18F-FGln identified improved diagnostic performance than 18F-FDG (AUC: 0.92 vs. 0.62). Metastatic lymph nodes showed higher 18F-FGln uptake, with increased SUVmax (3.57 ± 1.23 vs. 2.03 ± 0.47, P < 0.001) and TBR (2.11 ± 0.92 vs. 0.93 ± 0.21, P < 0.001). Multivariate analysis identified 18F-FGln SUVmax (OR = 32.79, P < 0.001) and CT density (OR = 0.90, P < 0.001) were predictors of metastatic lymph nodes (LNs). For distant metastases, 18F-FGln detected more distant lesions (86 vs. 70), particularly in bone (SUVmax 7.48 ± 3.03 vs. 6.80 ± 4.48) and brain (TBR 7.04 ± 2.96 vs. 0.88 ± 0.30, P < 0.001), altering staging in 3 cases. CONCLUSION: 18F-FGln PET/CT showed promising clinical potential in lung cancer, particularly in nodal staging, with higher diagnostic performance compared with 18F-FDG. It also demonstrated improved detection of bone and cerebral metastases in selected patients. Furthermore, 18F-FGln uptake correlated with CT-derived texture features, especially kurtosis, suggesting a possible association with tumor heterogeneity. Despite several false-negative cases, these results indicate that 18F-FGln may serve as a complementary metabolic imaging biomarker in lung cancer. Multicenter validation studies are needed to confirm these findings. CLINICAL TRIALS REGISTRATION: ChiCTR2000037834 Retrospectively Reg Date:2020-09-02.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Key laboratory of Carcinogenesis and Translational Research (Ministry of Education), Beijing Key Laboratory of Research, Investigation and Evaluation of Radiopharmaceuticals, NMPA Key Laboratory for Research and Evaluat…
Förderung
- National Natural Science Foundation of China
- Beijing Hospitals Authority's Ascent Plan
- Beijing Hospitals Authority’s Ascent Plan
Zitieren
APA
Xu, X., Liu, F., Xie, Q., Liu, S., Li, N., & Yang, Z. (2026). Preliminary clinical investigation of 18F-(2S,4R)-4-fluoroglutamine PET/CT in the evaluation of lung cancer. European Journal of Nuclear Medicine and Molecular Imaging, 53(13), 8166-8176. https://doi.org/10.1007/s00259-026-08107-7
Vancouver
Xu X, Liu F, Xie Q, Liu S, Li N, Yang Z. Preliminary clinical investigation of 18F-(2S,4R)-4-fluoroglutamine PET/CT in the evaluation of lung cancer. European Journal of Nuclear Medicine and Molecular Imaging. 2026;53(13):8166-8176. doi:10.1007/s00259-026-08107-7
BibTeX
@article{Xu2026,
author = {Xu, Xiaoxia and Liu, Futao and Xie, Qing and Liu, Song and Li, Nan and Yang, Zhi},
title = {Preliminary clinical investigation of 18F-(2S,4R)-4-fluoroglutamine PET/CT in the evaluation of lung cancer},
journal = {European Journal of Nuclear Medicine and Molecular Imaging},
year = {2026},
volume = {53},
number = {13},
pages = {8166--8176},
doi = {10.1007/s00259-026-08107-7}
}
EUVIMED